AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32089486 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month recall version of the Premature Ejaculation Profile (PEP)
Number of subjects: 0
Study 32089486 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term event-driven version of the Premature Ejaculation Profile (PEP)
Number of subjects: 0
Study 32089486 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal ejaculatory latency time (IELT)
Number of subjects: 0
Study 32089486 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Global Impression of Change (CGIC)
Number of subjects: 0
Study 35264025 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training program (12 weeks duration)
Number of subjects: 51
Study 35264025 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training program
Number of subjects: 51
Study 35213415 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB-L + BRAF WT
Number of subjects: 85
Study 35213415 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB-L + NRAS mut
Number of subjects: 85
Study 35213415 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB-L tumors
Number of subjects: 85
Study 34072223 — intervention group
Group type: EXPERIMENTAL
Intervention: One-off application of a structured 5-step implicit process to simplify medication regimens.
Number of subjects: 25
Study 34072223 — intervention group
Group type: EXPERIMENTAL
Intervention: One-off implicit medication simplification intervention.
Number of subjects: 25
Study 34072223 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of simplification recommendations.
Number of subjects: 25
Study 34072223 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder perceptions of regimen simplification.
Number of subjects: 25
Study 33973009 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-sensitive agroecology intervention
Number of subjects: 591
Study 32822460 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography Angiography
Number of subjects: 568
Study 32822460 — intervention group
Group type: COMPARATOR
Intervention: Exercise Electrocardiography (ECG) alone
Number of subjects: 568
Study 36159305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram prognostic model for overall survival (OS)
Number of subjects: 29736
Study 36159305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram prognostic model for cancer-specific survival (CSS)
Number of subjects: 29736
Study 36159305 — intervention group
Group type: COMPARATOR
Intervention: Nomogram compared to traditional TNM staging
Number of subjects: 29736
Study 33035492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 20 mg/kg
Number of subjects: 50
Study 33035492 — intervention group
Group type: COMPARATOR
Intervention: Intravenous normal saline (0.09%)
Number of subjects: 50
Study 34181143 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mg melatonin
Number of subjects: 196
Study 34181143 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mg melatonin
Number of subjects: 196
Study 34181143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 32449924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 8228
Study 33392653 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D endoscopy
Number of subjects: 16
Study 33392653 — intervention group
Group type: COMPARATOR
Intervention: 2D endoscopy
Number of subjects: 16
Study 35190270 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemon essential oil (smelled for 15 min)
Number of subjects: 46
Study 35190270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 34859852 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus Vitamin D supplementation
Number of subjects: 0
Study 34859852 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without Vitamin D
Number of subjects: 0
Study 32200759 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare delivery model targeting multiple stroke risk factors
Number of subjects: 275
Study 32200759 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 275
Study 32200759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (experimental and usual care)
Number of subjects: 275
Study 34033212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50 mg once daily
Number of subjects: 220
Study 34033212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 32485753 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants told the patient was hypotensive
Number of subjects: 85
Study 32485753 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants told the patient was hypertensive
Number of subjects: 85
Study 33774696 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted self-reported moderate to vigorous physical activity (PA)
Number of subjects: 42
Study 33774696 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted accelerometer-based physical activity
Number of subjects: 42
Study 33774696 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted accelerometer fraction of accelerations > 425 milli-gravities
Number of subjects: 42
Study 33774696 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted sedentary behavior
Number of subjects: 42
Study 32155878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet that was also gluten-free (low FODMAP-GFD)
Number of subjects: 30
Study 32155878 — intervention group
Group type: COMPARATOR
Intervention: Gluten/placebo challenge
Number of subjects: 30
Study 35334848 — intervention group
Group type: EXPERIMENTAL
Intervention: Saw palmetto berry extract (SPE) for 12 weeks
Number of subjects: 0
Study 35334848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32864597 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening-Night Closed-Loop Control (E-N CLC)
Number of subjects: 80
Study 32864597 — intervention group
Group type: COMPARATOR
Intervention: 24-7 Closed-Loop Control (24-7 CLC)
Number of subjects: 80
Study 32864597 — intervention group
Group type: COMPARATOR
Intervention: Sensor-Augmented Pump Therapy (SAP)
Number of subjects: 80
Study 35289723 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIE (4 × 4 minutes on cycle ergometer with 3 minutes active recovery)
Number of subjects: 49
Study 35289723 — intervention group
Group type: COMPARATOR
Intervention: Control (relaxed for the time equivalent to intervention)
Number of subjects: 49
Study 32917540 — intervention group
Group type: EXPERIMENTAL
Intervention: Music during surgical task
Number of subjects: 19
Study 32917540 — intervention group
Group type: COMPARATOR
Intervention: No music during surgical task
Number of subjects: 19
Study 32917540 — intervention group
Group type: COMPARATOR
Intervention: Comparison of music vs no music
Number of subjects: 19
Study 32101272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy (PG) with externalized stent
Number of subjects: 72
Study 32101272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticojejunostomy (PJ) with externalized stent
Number of subjects: 72
Study 36307274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 188
Study 36307274 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle plus medication therapy management
Number of subjects: 188
Study 36307274 — intervention group
Group type: COMPARATOR
Intervention: Social services
Number of subjects: 188
Study 36307274 — intervention group
Group type: EXPERIMENTAL
Intervention: All three groups
Number of subjects: 188
Study 34902548 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic immersive pain relief skills VR program
Number of subjects: 0
Study 34902548 — intervention group
Group type: COMPARATOR
Intervention: Sham VR program
Number of subjects: 0
Study 32456702 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative video
Number of subjects: 1024
Study 32456702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 1024
Study 35913904 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear pedagogy
Number of subjects: 162
Study 35913904 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear pedagogy
Number of subjects: 162
Study 35913904 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 162
Study 35587681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen inhalation
Number of subjects: 60
Study 35587681 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine combined with flurbiprofen axetil sedation and analgesia
Number of subjects: 60
Study 33001381 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatz3® adjustable intragastric balloon (IGB) with upward adjustment (250 mL greater volume)
Number of subjects: 180
Study 33001381 — intervention group
Group type: COMPARATOR
Intervention: Spatz3® adjustable intragastric balloon (IGB) with constant volume (600 mL)
Number of subjects: 180
Study 35820753 — intervention group
Group type: EXPERIMENTAL
Intervention: Group aerobic exercise delivered by exercise professionals and supported by mental health workers for 1 hour three times a week for 12 weeks
Number of subjects: 122
Study 35820753 — intervention group
Group type: COMPARATOR
Intervention: Leisure activities led by mental health workers for 1 hour three times a week for 12 weeks (Control)
Number of subjects: 122
Study 35820753 — intervention group
Group type: EXPERIMENTAL
Intervention: Group aerobic exercise
Number of subjects: 122
Study 34407530 — intervention group
Group type: EXPERIMENTAL
Intervention: CytoSorb hemoperfusion
Number of subjects: 10
Study 36083392 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Physical Training (CPT)
Number of subjects: 16
Study 36083392 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 32562076 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) at 200-mW, 6-J, continuous-wave mode for 30 seconds
Number of subjects: 45
Study 32562076 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 45
Study 36045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Propofol
Number of subjects: 155
Study 36045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Ketamine
Number of subjects: 155
Study 36045520 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam, Ketamine, and Magnesium
Number of subjects: 155
Study 36045520 — intervention group
Group type: COMPARATOR
Intervention: Control group (Midazolam)
Number of subjects: 155
Study 33902519 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-based intervention group (N=59; communicating with PDS and attending the lecture)
Number of subjects: 115
Study 33902519 — intervention group
Group type: COMPARATOR
Intervention: Educational lecture group (N=56; only attending a lecture on schizophrenia)
Number of subjects: 115
Study 33902519 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact-based intervention group (N=59)
Number of subjects: 115
Study 33902519 — intervention group
Group type: COMPARATOR
Intervention: Educational lecture group (N=56)
Number of subjects: 115
Study 35988206 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine infusion through aortic root
Number of subjects: 86
Study 35988206 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 86
Study 32503620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (Kaletra) + Colchicine 1.5 mg loading then 0.5 mg twice daily orally
Number of subjects: 80
Study 32503620 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (Kaletra)
Number of subjects: 80
Study 32503620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (Kaletra) + Colchicine
Number of subjects: 80
Study 33259999 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal high-intensity focused ultrasound (vHIFU) therapy
Number of subjects: 13
Study 32827221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1Hz rTMS
Number of subjects: 51
Study 32827221 — intervention group
Group type: EXPERIMENTAL
Intervention: 25Hz rTMS
Number of subjects: 51
Study 32827221 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 51
Study 35947124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative practice
Number of subjects: 60
Study 35947124 — intervention group
Group type: COMPARATOR
Intervention: Individual practice
Number of subjects: 60
Study 33877743 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg daily for 7 days)
Number of subjects: 30
Study 33877743 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (300 mg daily for 7 days)
Number of subjects: 30
Study 33877743 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotics given)
Number of subjects: 30
Study 32393964 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV)
Number of subjects: 396
Study 32393964 — intervention group
Group type: COMPARATOR
Intervention: Non-Bevacizumab (non-BEV)
Number of subjects: 396
Study 32969703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program, 8-week duration
Number of subjects: 29
Study 32969703 — intervention group
Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 29
Study 36184023 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 long‐chained polyunsaturated fatty acid (n‐3 LCPUFA) (fish oil)
Number of subjects: 736
Study 36184023 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (2800 IU/d)
Number of subjects: 736
Study 33309538 — intervention group
Group type: EXPERIMENTAL
Intervention: CB-Abst (cannabis abstinence through contingency management)
Number of subjects: 160
Study 33309538 — intervention group
Group type: COMPARATOR
Intervention: CB-Mon (monitoring with no abstinence requirement)
Number of subjects: 160
Study 32539288 — intervention group
Group type: EXPERIMENTAL
Intervention: 33% of daily TAF (25 mg)/FTC (200 mg)
Number of subjects: 37
Study 32539288 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% of daily TAF (25 mg)/FTC (200 mg)
Number of subjects: 37
Study 32539288 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% of daily TAF (25 mg)/FTC (200 mg)
Number of subjects: 37
Study 32451321 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 1670
Study 32451321 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1670
Study 35379302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirasol-treated whole blood (n = 1000)
Number of subjects: 2000
Study 35379302 — intervention group
Group type: COMPARATOR
Intervention: Standard whole blood (n = 1000)
Number of subjects: 2000
Study 33104016 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagonal eccentric contraction intervention (IEDEC)
Number of subjects: 25
Study 33104016 — intervention group
Group type: COMPARATOR
Intervention: General exercise intervention (IGE)
Number of subjects: 25
Study 32619212 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium
Number of subjects: 14
Study 32619212 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 14
Study 32619212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nopal
Number of subjects: 14
Study 35399102 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing intervention
Number of subjects: 150
Study 33439219 — intervention group
Group type: EXPERIMENTAL
Intervention: PE-owned clinics (BCBS)
Number of subjects: 1833
Study 33439219 — intervention group
Group type: EXPERIMENTAL
Intervention: PE-owned clinics (Medicare)
Number of subjects: 1833
Study 33439219 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (BCBS)
Number of subjects: 1833
Study 33439219 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (Medicare)
Number of subjects: 1833
Study 33439219 — intervention group
Group type: EXPERIMENTAL
Intervention: PE-owned clinics (Medicaid)
Number of subjects: 1833
Study 33439219 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (Medicaid)
Number of subjects: 1833
Study 33439219 — intervention group
Group type: EXPERIMENTAL
Intervention: PE-owned clinics (new patient appointments with NPCs)
Number of subjects: 1833
Study 33439219 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (new patient appointments with NPCs)
Number of subjects: 1833
Study 33439219 — intervention group
Group type: EXPERIMENTAL
Intervention: PE-owned clinics (next-day appointment availability)
Number of subjects: 1833
Study 33439219 — intervention group
Group type: COMPARATOR
Intervention: Control clinics (next-day appointment availability)
Number of subjects: 1833
Study 33565885 — intervention group
Group type: EXPERIMENTAL
Intervention: LSG + PF (posterior fixation with fibrin tissue glue)
Number of subjects: 191
Study 33565885 — intervention group
Group type: COMPARATOR
Intervention: LSG alone (traditional technique)
Number of subjects: 191
Study 34507074 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid streptococcal antigen test
Number of subjects: 519
Study 34507074 — intervention group
Group type: COMPARATOR
Intervention: Usual diagnostic‐therapeutic algorithm (Control)
Number of subjects: 519
Study 34507074 — intervention group
Group type: COMPARATOR
Intervention: Control group (Usual diagnostic‐therapeutic algorithm)
Number of subjects: 519
Study 35318006 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33 °C for 24 hours
Number of subjects: 159
Study 35318006 — intervention group
Group type: COMPARATOR
Intervention: Targeted normothermia at 37 °C for 48 hours
Number of subjects: 159
Study 35318006 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33 °C
Number of subjects: 159
Study 35318006 — intervention group
Group type: COMPARATOR
Intervention: Targeted normothermia at 37 °C
Number of subjects: 159
Study 32068049 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sofpironium bromide gel
Number of subjects: 0
Study 32068049 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sofpironium bromide gel
Number of subjects: 0
Study 32068049 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% sofpironium bromide gel
Number of subjects: 0
Study 32068049 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 32332634 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine foot bath decoction (FBD) with ordinary dressing changes
Number of subjects: 60
Study 32332634 — intervention group
Group type: COMPARATOR
Intervention: Placebo with ordinary dressings
Number of subjects: 60
Study 32332634 — intervention group
Group type: COMPARATOR
Intervention: Placebo with silver ion dressings
Number of subjects: 60
Study 36306329 — intervention group
Group type: EXPERIMENTAL
Intervention: NETfacts health system (integrated model of Narrative Exposure Therapy and community-based intervention)
Number of subjects: 1066
Study 36306329 — intervention group
Group type: COMPARATOR
Intervention: Individual NET alone
Number of subjects: 1066
Study 34930153 — intervention group
Group type: EXPERIMENTAL
Intervention: Astra‐Zeneca ChAdOx1 vaccine
Number of subjects: 50
Study 34930153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfizer BNT162b2 vaccine
Number of subjects: 50
Study 32517117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal avatar (IAC)
Number of subjects: 42
Study 32517117 — intervention group
Group type: EXPERIMENTAL
Intervention: Real avatar (RAC)
Number of subjects: 42
Study 32517117 — intervention group
Group type: COMPARATOR
Intervention: Non avatar (NAC)
Number of subjects: 42
Study 35318632 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia insulin pen-injector health education intervention
Number of subjects: 72
Study 35318632 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard education)
Number of subjects: 72
Study 32741502 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 40-IU administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions
Number of subjects: 48
Study 32741502 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions
Number of subjects: 48
Study 34101252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutrition treatment (INT) with protein intake of 1.70 ± 0.21 g/kg/d
Number of subjects: 41
Study 34101252 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition treatment (SNT) with protein intake of 1.06 ± 0.21 g/kg/d
Number of subjects: 41
Study 34872511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days plus standard of care (SOC) treatment
Number of subjects: 105
Study 34872511 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment alone
Number of subjects: 105
Study 34872511 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 105
Study 34714508 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component community intervention including social marketing targeting adolescents and parents, and community intervention to reduce underage alcohol sales.
Number of subjects: 3377
Study 34714508 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to social marketing
Number of subjects: 3377
Study 34714508 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component community intervention
Number of subjects: 3377
Study 34714508 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents setting a rule
Number of subjects: 3377
Study 34714508 — intervention group
Group type: EXPERIMENTAL
Intervention: Total indirect effects from the intervention
Number of subjects: 3377
Study 34714508 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents not supplying alcohol
Number of subjects: 3377
Study 33155057 — intervention group
Group type: EXPERIMENTAL
Intervention: Green light-emitting diodes (GLED) for 1 to 2 hours daily for 10 weeks
Number of subjects: 21
Study 33155057 — intervention group
Group type: COMPARATOR
Intervention: White light-emitting diodes
Number of subjects: 21
Study 36395875 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus ticagrelor (AT group)
Number of subjects: 278
Study 36395875 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel (AC group)
Number of subjects: 278